rosiglitazone (Avandia)

Subscribe to Selected New Research on rosiglitazone

1117 relevant articles (139 outcomes, 278 trials/studies) found for this Drug

Description: a peroxisome proliferator-activated receptor gamma agonist; reduces lipid availability, improves insulin action & glucoregulation; Avandia is tradename for the rosiglitazone maleate

Also Known As:

Avandia; 5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate; BRL 49653; BRL-49653; BRL49653; Glaxo Wellcome brand of rosiglitazone maleate; GlaxoSmithKline brand of rosiglitazone maleate; SmithKline Beecham brand of rosiglitazone maleate; rosiglitazone maleate; 2,4-Thiazolidinedione, 5-004-02-((((methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 42

Sulfur Compounds: 87

Thiazoles: 12

Thiazolidinediones: 890

rosiglitazone: 1117

Heterocyclic Compounds: 25

1-Ring Heterocyclic Compounds

Azoles: 243

Thiazoles: 12

Thiazolidinediones: 890

rosiglitazone: 1117

Experts

1.	Cha, Bong Soo: 8 articles (07/2008 - 01/2005)
2.	Lee, Hyun Chul: 7 articles (07/2008 - 01/2005)
3.	Ahn, Chul Woo: 7 articles (07/2008 - 01/2005)
4.	Derosa, Giuseppe: 7 articles (05/2008 - 05/2004)
5.	Ciccarelli, Leonardina: 7 articles (05/2008 - 05/2004)
6.	Piccinni, Mario N: 7 articles (05/2008 - 05/2004)
7.	Kang, Eun Seok: 6 articles (07/2008 - 02/2006)
8.	Cicero, Arrigo F G: 6 articles (11/2006 - 05/2004)
9.	Shim, Wan Sub: 5 articles (07/2008 - 02/2006)
10.	Kim, Soo Kyung: 5 articles (07/2008 - 01/2005)

Related Diseases

1.	Insulin Resistance 07/01/2005 - "Insulin resistance indices were significantly improved after rosiglitazone treatment (P < 0.05). " 08/01/1997 - "BRL 49653 ameliorates insulin resistance and improves glucoregulation in high-fat-fed (HF) rats. " 09/01/1999 - "Rosiglitazone is effective against insulin resistance]" 09/01/2007 - "RESULTS: As expected, rosiglitazone improved insulin resistance and postprandial hyperglycaemia. " 01/01/2005 - "Rosiglitazone monotherapy improved insulin resistance but not overall beta-cell secretion. " Order ALL the reference details at left...
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2005 - "Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus." 10/01/2007 - "The objective of this study was to determine if rosiglitazone (RSG) reduced the odds of restenosis and if RSG improved the odds of clinical outcomes after percutaneous coronary intervention (PCI) in type 2 diabetes mellitus (DM) patients. " 09/01/2003 - "OBJECTIVE: To assess the clinical safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus. " 09/01/2003 - "[The safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus in China]" 01/01/2007 - "Published studies of at least 24 weeks rosiglitazone treatment in people with type 2 diabetes mellitus did not provide evidence that patient-oriented outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life are positively influenced by this compound. " Order ALL the reference details at left...
3.	Inflammation 04/01/2008 - "A significant reduction in HOMA-R, markers of inflammation and oxidative stress was only observed with rosiglitazone. " 07/15/2004 - "Thus, rosiglitazone reduced markers of inflammation and endothelial activation, but this did not translate into an improvement in FMD. " 03/01/2008 - "Rosiglitazone increases matrix production and quenches inflammation: studies in human cells." 10/01/2009 - "The reduction of microvascular damage and inflammation contributes to the beneficial actions of rosiglitazone." 04/01/2009 - "Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction." Order ALL the reference details at left...
4.	Body Weight (Weight, Body) 09/01/2007 - "Rosiglitazone (Rosi), despite marked improvement in glycaemia, hyperinsulinaemia and hyperlipidaemia, failed to affect SREBP-1 expression, and increased body weight and IMTG. " 08/01/2000 - "The two rexinoids also produced a marked decrease in the body weight gain, whereas the growth rate of rats treated with BRL 49653 tended to increase. " 10/01/2006 - "The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. " 10/30/2009 - "Moreover, rosiglitazone did not increase body weight and WAT weight in VLDLR-deficient mice. " 10/30/2009 - "In ob/ob mice, body weight and WAT weight were significantly higher in the mice treated with rosiglitazone than those treated with vehicle. " Order ALL the reference details at left...
5.	Syndrome 05/01/2006 - "CONCLUSIONS: Rosiglitazone might be effective in reducing the prevalence of the metabolic syndrome." 05/01/2006 - "After 12 months, subjects with the metabolic syndrome receiving rosiglitazone showed improved flow-mediated vasodilation (4.2%, P < 0.001) and reduced hs-CRP levels (-0.7 mg/dl, P = 0.04), compared with the placebo group. " 05/01/2006 - "OBJECTIVE: The aim of this study was to assess the effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. " 07/01/2007 - "METHODS: A total of 200 patients with metabolic syndrome undergoing PCI were randomized to rosiglitazone or placebo and followed for 1 year. " 05/01/2007 - "Ineffectiveness of rosiglitazone therapy in Nelson's syndrome." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	PPAR gamma
3.	Metformin (Glucophage)
4.	Glucose (Dextrose)
5.	pioglitazone (Actos)
6.	Adiponectin
7.	Glyburide (Glibenclamide)
8.	Thiazolidinediones
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10.	Procetofen (CiL)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Transplants (Transplant)
3.	Peritoneal Dialysis
4.	Kidney Transplantation
5.	Homologous Transplantation (Allograft)

Best Treatments:
Research Summary Report
on Insulin Resistance

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 979 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>